FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:549-557 February 10, 2005 Number 6 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Perspective by Cazzola, M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes. Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with myelodysplastic syndromes and symptomatic anemia, we evaluated the safety and hematologic activity of lenalidomide, a novel analogue of thalidomide.

Methods Forty-three patients with transfusion-dependent or symptomatic anemia received lenalidomide at doses of 25 or 10 mg per day or of 10 mg per day for 21 days of every 28-day cycle. All patients either had had no response to recombinant erythropoietin or had a high endogenous erythropoietin level with a low probability of benefit from such therapy. The response to treatment was assessed after 16 weeks.

Results Neutropenia and thrombocytopenia, the most common adverse events, with respective frequencies of 65 percent and 74 percent, necessitated the interruption of treatment or a dose reduction in 25 patients (58 percent). Other adverse events were mild and infrequent. Twenty-four patients had a response (56 percent): 20 had sustained independence from transfusion, 1 had an increase in the hemoglobin level of more than 2 g per deciliter, and 3 had more than a 50 percent reduction in the need for transfusions. The response rate was highest among patients with a clonal interstitial deletion involving chromosome 5q31.1 (83 percent, as compared with 57 percent among those with a normal karyotype and 12 percent among those with other karyotypic abnormalities; P=0.007) and patients with lower prognostic risk. Of 20 patients with karyotypic abnormalities, 11 had at least a 50 percent reduction in abnormal cells in metaphase, including 10 (50 percent) with a complete cytogenetic remission. After a median follow-up of 81 weeks, the median duration of transfusion independence had not been reached and the median hemoglobin level was 13.2 g per deciliter (range, 11.5 to 15.8).

Conclusions Lenalidomide has hematologic activity in patients with low-risk myelodysplastic syndromes who have no response to erythropoietin or who are unlikely to benefit from conventional therapy.

Source Information

From the Department of Interdisciplinary Oncology, University of South Florida and the H. Lee Moffitt Cancer Center and Research Institute, Tampa (A.L., R.H.); the Departments of Medicine and Pathology, University of Arizona College of Medicine, Tucson (S.K., A.B., D.M., D.F., L.R.); the Mel and Enid Zuckerman Arizona College of Public Health, Tucson (D.J.R.); and Celgene, Warren, N.J. (R.K., J.B.Z.).

Address reprint requests to Dr. List at the Hematologic Malignancies Program, SRB Rm. 24038, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr., Tampa, FL 33612-9497, or at listaf{at}moffitt.usf.edu.

Full Text of this Article

Related Letters:

Treatment of Myelodysplastic Syndromes
Chng W. J., Stadler M., Ganser A., List A. F., Cazzola M., Malcovati L.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2134-2135, May 19, 2005. Correspondence

This article has been cited by other articles:

• Quintas-Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D., Cortes, J., Ravandi, F., Garcia-Manero, G., Ferrajoli, A., Bueso-Ramos, C., Verstovsek, S. (2009). Lenalidomide Plus Prednisone Results in Durable Clinical, Histopathologic, and Molecular Responses in Patients With Myelofibrosis. JCO 27: 4760-4766 [Abstract] [Full Text]  
• Escoubet-Lozach, L., Lin, I-L., Jensen-Pergakes, K., Brady, H. A., Gandhi, A. K., Schafer, P. H., Muller, G. W., Worland, P. J., Chan, K. W.H., Verhelle, D. (2009). Pomalidomide and Lenalidomide Induce p21WAF-1 Expression in Both Lymphoma and Multiple Myeloma through a LSD1-Mediated Epigenetic Mechanism. Cancer Res. 69: 7347-7356 [Abstract] [Full Text]  
• Wei, S., Chen, X., Rocha, K., Epling-Burnette, P. K., Djeu, J. Y., Liu, Q., Byrd, J., Sokol, L., Lawrence, N., Pireddu, R., Dewald, G., Williams, A., Maciejewski, J., List, A. (2009). A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc. Natl. Acad. Sci. USA 106: 12974-12979 [Abstract] [Full Text]  
• Nosslinger, T., Tuchler, H., Germing, U., Sperr, W. R., Krieger, O., Haase, D., Lubbert, M., Stauder, R., Giagounidis, A., Valent, P., Pfeilstocker, M. (2009). Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 0: mdp264v1-mdp264 [Abstract] [Full Text]  
• Xu, Y., Li, J., Ferguson, G. D., Mercurio, F., Khambatta, G., Morrison, L., Lopez-Girona, A., Corral, L. G., Webb, D. R., Bennett, B. L., Xie, W. (2009). Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases. Blood 114: 338-345 [Abstract] [Full Text]  
• Dahut, W. L., Aragon-Ching, J. B., Woo, S., Tohnya, T. M., Gulley, J. L., Arlen, P. M., Wright, J. J., Ventiz, J., Figg, W. D. (2009). Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer. J Clin Pharmacol 49: 650-660 [Abstract] [Full Text]  
• Mesa, R. A. (2009). How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood 113: 5394-5400 [Abstract] [Full Text]  
• Delmonte, A., Ghielmini, M., Sessa, C. (2009). Beyond Monoclonal Antibodies: New Therapeutic Agents in Non-Hodgkin's Lymphomas. The Oncologist 14: 511-525 [Abstract] [Full Text]  
• Mohr, B., Oelschlaegel, U., Thiede, C., Stewart, M. M., Ehninger, G., Platzbecker, U. (2009). The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells. haematol 94: 430-431 [Full Text]  
• Mesa, R. A., Hanson, C. A., Ketterling, R. P., Schwager, S., Knudson, R. A., Tefferi, A. (2009). Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality. Blood 113: 1200-1201 [Full Text]  
• Fehniger, T. A., Byrd, J. C., Marcucci, G., Abboud, C. N., Kefauver, C., Payton, J. E., Vij, R., Blum, W. (2009). Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13. Blood 113: 1002-1005 [Abstract] [Full Text]  
• Garcia-Manero, G. (2009). Standard-of-care Approaches for Myelodysplastic Syndromes. Am Soc Clin Oncol Ed Book 2009: 408-412 [Abstract] [Full Text]  
• Lapalombella, R., Yu, B., Triantafillou, G., Liu, Q., Butchar, J. P., Lozanski, G., Ramanunni, A., Smith, L. L., Blum, W., Andritsos, L., Wang, D.-S., Lehman, A., Chen, C.-S., Johnson, A. J., Marcucci, G., Lee, R. J., Lee, L. J., Tridandapani, S., Muthusamy, N., Byrd, J. C. (2008). Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells. Blood 112: 5180-5189 [Abstract] [Full Text]  
• Cazzola, M. (2008). Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. haematol 93: 967-972 [Full Text]  
• Mallo, M., Arenillas, L., Espinet, B., Salido, M., Hernandez, J. M{a}, Lumbreras, E., del Rey, M., Arranz, E., Ramiro, S., Font, P., Gonzalez, O., Renedo, M., Cervera, J., Such, E., Sanz, G. F., Luno, E., Sanzo, C., Gonzalez, M., Calasanz, M. J., Mayans, J., Garcia-Ballesteros, C., Amigo, V., Collado, R., Oliver, I., Carbonell, F., Bureo, E., Insunza, A., Yanez, L., Muruzabal, M. J., Gomez-Beltran, E., Andreu, R., Leon, P., Gomez, V., Sanz, A., Casasola, N., Moreno, E., Alegre, A., Martin, M. L., Pedro, C., Serrano, S., Florensa, L., Sole, F. (2008). Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-. haematol 93: 1001-1008 [Abstract] [Full Text]  
• Ferrajoli, A., Lee, B.-N., Schlette, E. J., O'Brien, S. M., Gao, H., Wen, S., Wierda, W. G., Estrov, Z., Faderl, S., Cohen, E. N., Li, C., Reuben, J. M., Keating, M. J. (2008). Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111: 5291-5297 [Abstract] [Full Text]  
• Sloand, E. M., Wu, C. O., Greenberg, P., Young, N., Barrett, J. (2008). Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy. JCO 26: 2505-2511 [Abstract] [Full Text]  
• Andritsos, L. A., Johnson, A. J., Lozanski, G., Blum, W., Kefauver, C., Awan, F., Smith, L. L., Lapalombella, R., May, S. E., Raymond, C. A., Wang, D.-S., Knight, R. D., Ruppert, A. S., Lehman, A., Jarjoura, D., Chen, C.-S., Byrd, J. C. (2008). Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia. JCO 26: 2519-2525 [Abstract] [Full Text]  
• Nimer, S. D. (2008). Myelodysplastic syndromes. Blood 111: 4841-4851 [Abstract] [Full Text]  
• Gondek, L. P., Tiu, R., O'Keefe, C. L., Sekeres, M. A., Theil, K. S., Maciejewski, J. P. (2008). Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood 111: 1534-1542 [Abstract] [Full Text]  
• Kurzrock, R., Kantarjian, H. M., Blascovich, M. A., Bucher, C., Verstovsek, S., Wright, J. J., Pilat, S. R., Cortes, J. E., Estey, E. H., Giles, F. J., Beran, M., Sebti, S. M. (2008). Phase I Study of Alternate-Week Administration of Tipifarnib in Patients with Myelodysplastic Syndrome. Clin. Cancer Res. 14: 509-514 [Abstract] [Full Text]  
• Park, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.-T., Cheze, S., Mahe, B., Ferrant, A., Ravoet, C., Escoffre-Barbe, M., Ades, L., Vey, N., Aljassem, L., Stamatoullas, A., Mannone, L., Dombret, H., Bourgeois, K., Greenberg, P., Fenaux, P., Dreyfus, F., for the GFM group (Groupe Francophone des Myelodys, (2008). Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 111: 574-582 [Abstract] [Full Text]  
• Kroger, N. (2008). Epigenetic Modulation and Other Options to Improve Outcome of Stem Cell Transplantation in MDS. ASH Education Book 2008: 60-67 [Abstract] [Full Text]  
• O'Brien, S. (2008). New Agents in the Treatment of CLL. ASH Education Book 2008: 457-464 [Abstract] [Full Text]  
• Raza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, H. J., Dreisbach, L., Schiffer, C. A., Stone, R. M., Greenberg, P. L., Curtin, P. T., Klimek, V. M., Shammo, J. M., Thomas, D., Knight, R. D., Schmidt, M., Wride, K., Zeldis, J. B., List, A. F. (2008). Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 111: 86-93 [Abstract] [Full Text]  
• Haase, D., Germing, U., Schanz, J., Pfeilstocker, M., Nosslinger, T., Hildebrandt, B., Kundgen, A., Lubbert, M., Kunzmann, R., Giagounidis, A. A. N., Aul, C., Trumper, L., Krieger, O., Stauder, R., Muller, T. H., Wimazal, F., Valent, P., Fonatsch, C., Steidl, C. (2007). New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 110: 4385-4395 [Abstract] [Full Text]  
• Chen, N., Lau, H., Kong, L., Kumar, G., Zeldis, J. B., Knight, R., Laskin, O. L. (2007). Pharmacokinetics of Lenalidomide in Subjects With Various Degrees of Renal Impairment and in Subjects on Hemodialysis. J Clin Pharmacol 47: 1466-1475 [Abstract] [Full Text]  
• Sorror, M. L., Sandmaier, B. M., Storer, B. E., Maris, M. B., Baron, F., Maloney, D. G., Scott, B. L., Deeg, H. J., Appelbaum, F. R., Storb, R. (2007). Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. JCO 25: 4246-4254 [Abstract] [Full Text]  
• Pellagatti, A., Jadersten, M., Forsblom, A.-M., Cattan, H., Christensson, B., Emanuelsson, E. K., Merup, M., Nilsson, L., Samuelsson, J., Sander, B., Wainscoat, J. S., Boultwood, J., Hellstrom-Lindberg, E. (2007). Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc. Natl. Acad. Sci. USA 104: 11406-11411 [Abstract] [Full Text]  
• Bacher, U., Haferlach, T., Kern, W., Haferlach, C., Schnittger, S. (2007). A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. haematol 92: 744-752 [Abstract] [Full Text]  
• Estey, E. (2007). Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients. JCO 25: 1908-1915 [Abstract] [Full Text]  
• Thornburg, A., Abonour, R., Smith, P., Knox, K., Twigg, H. L. III (2007). Hypersensitivity Pneumonitis-Like Syndrome Associated With the Use of Lenalidomide. Chest 131: 1572-1574 [Abstract] [Full Text]  
• Verhelle, D., Corral, L. G., Wong, K., Mueller, J. H., Moutouh-de Parseval, L., Jensen-Pergakes, K., Schafer, P. H., Chen, R., Glezer, E., Ferguson, G. D., Lopez-Girona, A., Muller, G. W., Brady, H. A., Chan, K. W.H. (2007). Lenalidomide and CC-4047 Inhibit the Proliferation of Malignant B Cells while Expanding Normal CD34+ Progenitor Cells. Cancer Res. 67: 746-755 [Abstract] [Full Text]  
• Melchert, M., List, A. F. (2007). Management of RBC-Transfusion Dependence. ASH Education Book 2007: 398-404 [Abstract] [Full Text]  
• Shannon, K., Silverman, L. R. (2007). Myelodysplastic syndrome and overlap syndromes. ASH-SAP 2007: 228-242 [Full Text]  
• Navas, T. A., Mohindru, M., Estes, M., Ma, J. Y., Sokol, L., Pahanish, P., Parmar, S., Haghnazari, E., Zhou, L., Collins, R., Kerr, I., Nguyen, A. N., Xu, Y., Platanias, L. C., List, A. A., Higgins, L. S., Verma, A. (2006). Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 108: 4170-4177 [Abstract] [Full Text]  
• Chanan-Khan, A., Miller, K. C., Musial, L., Lawrence, D., Padmanabhan, S., Takeshita, K., Porter, C. W., Goodrich, D. W., Bernstein, Z. P., Wallace, P., Spaner, D., Mohr, A., Byrne, C., Hernandez-Ilizaliturri, F., Chrystal, C., Starostik, P., Czuczman, M. S. (2006). Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. JCO 24: 5343-5349 [Abstract] [Full Text]  
• List, A. F., Dewald, G. W., Bennett, J. M., Giagounidis, A., Raza, A., Feldman, E. J., Powell, B. L., Greenberg, P. L., Nimer, S. D., Zeldis, J. B., Wride, K., Schmidt, M., Knight, R. D. (2006). Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.. ASH ANNUAL MEETING ABSTRACTS 108: 251-251 [Abstract]  
• List, A. F., Estes, M., Williams, A., Sekharam, M., Ozawa, U., Gao, G., Wu, J., Gao, G., Sokol, L. (2006). Lenalidomide (CC-5013; Revlimid(R)) Promotes Erythropoiesis in Myelodysplastic Syndromes (MDS) by CD45 Protein Tyrosine Phosphatase (PTP) Inhibition.. ASH ANNUAL MEETING ABSTRACTS 108: 1360-1360 [Abstract]  
• Epling-Burnette, P.K., Bai, F., Painter, J. S., Dana, R., Zou, J., Ku, E., Zhong, B., Wei, S., Djeu, J. Y., List, A. F. (2006). Reduced Natural Killer Function Accompanies MDS Disease Progression and Is Restored by Lenalidomide (CC5013, Revlimid(R)) Via a Mechanism Divergent from Interleukin-2 (IL-2).. ASH ANNUAL MEETING ABSTRACTS 108: 2651-2651 [Abstract]  
• Kelaidi, C., Park, S., Brechignac, S., Mannone, L., Vey, N., Dombret, H., Aljassem, L., Stamatoullas, A., Ades, L., Giraudier, S., de Botton, S., Mahe, B., Lepelley, P., Picard, F., Leroux, G., Daniel, M.-T., Bouscary, D., Dreyfus, F., Fenaux, P. (2006). Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience.. ASH ANNUAL MEETING ABSTRACTS 108: 2678-2678 [Abstract]  
• Mesa, R. A., Tefferi, A., Steensma, D. P. (2006). Hematologic and Cytogenetic Response to Lenalidomide Therapy in an 82 Year Old Female with Acute Myeloid Leukemia (AML) Arising from JAK2V617F Positive, del(5)(q13q33) Myelodysplastic Syndrome (MDS).. ASH ANNUAL MEETING ABSTRACTS 108: 4827-4827 [Abstract]  
• List, A., Dewald, G., Bennett, J., Giagounidis, A., Raza, A., Feldman, E., Powell, B., Greenberg, P., Thomas, D., Stone, R., Reeder, C., Wride, K., Patin, J., Schmidt, M., Zeldis, J., Knight, R., the Myelodysplastic Syndrome-003 Study Investigato, (2006). Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion. NEJM 355: 1456-1465 [Abstract] [Full Text]  
• Sviggum, H. P., Davis, M. D. P., Rajkumar, S. V., Dispenzieri, A. (2006). Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma.. Arch Dermatol 142: 1298-1302 [Abstract] [Full Text]  
• Tefferi, A., Barosi, G., Mesa, R. A., Cervantes, F., Deeg, H. J., Reilly, J. T., Verstovsek, S., Dupriez, B., Silver, R. T., Odenike, O., Cortes, J., Wadleigh, M., Solberg, L. A. Jr, Camoriano, J. K., Gisslinger, H., Noel, P., Thiele, J., Vardiman, J. W., Hoffman, R., Cross, N. C. P., Gilliland, D. G., Kantarjian, H. (2006). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood 108: 1497-1503 [Abstract] [Full Text]  
• Spivak, J. L. (2006). Lenalidomide and the 3 Ms: deja vu all over again?. Blood 108: 1118-1119 [Full Text]  
• Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., Byrne, C., Zeldis, J. B., Ketterling, R. P., McClure, R. F., Giles, F., Kantarjian, H. M. (2006). Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 108: 1158-1164 [Abstract] [Full Text]  
• Hoverson, A. R., Davis, M. D. P., Weenig, R. H., Wolanskyj, A. P. (2006). Neutrophilic dermatosis (sweet syndrome) of the hands associated with lenalidomide.. Arch Dermatol 142: 1070-1071 [Full Text]  
• Chang, D. H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S. D., Jagannath, S., Dhodapkar, M. V. (2006). Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 108: 618-621 [Abstract] [Full Text]  
• Cheson, B. D., Greenberg, P. L., Bennett, J. M., Lowenberg, B., Wijermans, P. W., Nimer, S. D., Pinto, A., Beran, M., de Witte, T. M., Stone, R. M., Mittelman, M., Sanz, G. F., Gore, S. D., Schiffer, C. A., Kantarjian, H. (2006). Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108: 419-425 [Abstract] [Full Text]  
• Traynor, B. J., Bruijn, L., Conwit, R., Beal, F., O'Neill, G., Fagan, S. C., Cudkowicz, M. E. (2006). Neuroprotective agents for clinical trials in ALS: A systematic assessment.. Neurology 67: 20-27 [Abstract] [Full Text]  
• Zonder, J. A., Barlogie, B., Durie, B. G. M., McCoy, J., Crowley, J., Hussein, M. A., Rajkumar, S. V., Gertz, M. A. (2006). Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.. Blood 108: 403-404 [Full Text]  
• Pellagatti, A., Cazzola, M., Giagounidis, A. A. N., Malcovati, L., Porta, M. G. D., Killick, S., Campbell, L. J., Wang, L., Langford, C. F., Fidler, C., Oscier, D., Aul, C., Wainscoat, J. S., Boultwood, J. (2006). Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood 108: 337-345 [Abstract] [Full Text]  
• Nimer, S. D. (2006). Clinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q. JCO 24: 2576-2582 [Abstract] [Full Text]  
• Schiller, G. J., Slack, J., Hainsworth, J. D., Mason, J., Saleh, M., Rizzieri, D., Douer, D., List, A. F. (2006). Phase II Multicenter Study of Arsenic Trioxide in Patients With Myelodysplastic Syndromes. JCO 24: 2456-2464 [Abstract] [Full Text]  
• Vey, N., Bosly, A., Guerci, A., Feremans, W., Dombret, H., Dreyfus, F., Bowen, D., Burnett, A., Dennis, M., Ribrag, V., Casadevall, N., Legros, L., Fenaux, P. (2006). Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study. JCO 24: 2465-2471 [Abstract] [Full Text]  
• Stone, R. M. (2006). Is Intravenous Arsenic Trioxide a Useful Therapy in Myelodysplastic Syndromes?. JCO 24: 2414-2416 [Full Text]  
• Cheson, B. D., Canellos, G. P. (2006). The cancer and leukemia group B lymphoma committee.. Clin. Cancer Res. 12: 3572s-3575s [Abstract] [Full Text]  
• Tefferi, A. (2006). Iron Chelation Therapy for Myelodysplastic Syndrome: If and When. Mayo Clin Proc. 81: 197-198 [Full Text]  
• Maier, S. K, Hammond, J. M (2006). Role of Lenalidomide in the Treatment of Multiple Myeloma and Myelodysplastic Syndrome. The Annals of Pharmacotherapy 40: 286-289 [Abstract] [Full Text]  
• Giagounidis, A. A.N., Germing, U., Aul, C. (2006). Biological and Prognostic Significance of Chromosome 5q Deletions in Myeloid Malignancies. Clin. Cancer Res. 12: 5-10 [Abstract] [Full Text]  
• Fenaux, P., Kelaidi, C. (2006). Treatment of the 5q- Syndrome. ASH Education Book 2006: 192-198 [Abstract] [Full Text]  
• Schiffer, C. A. (2006). Clinical Issues in the Management of Patients with Myelodysplasia. ASH Education Book 2006: 205-210 [Abstract] [Full Text]  
• Zonder, J. A. (2006). Thrombotic Complications of Myeloma Therapy. ASH Education Book 2006: 348-355 [Abstract] [Full Text]  
• Steensma, D. P., Bennett, J. M. (2006). The Myelodysplastic Syndromes: Diagnosis and Treatment. Mayo Clin Proc. 81: 104-130 [Abstract] [Full Text]  
• Tefferi, A. (2005). Pathogenesis of Myelofibrosis With Myeloid Metaplasia. JCO 23: 8520-8530 [Abstract] [Full Text]  
• Wang, H., Naing, A., Cheng, F., Horna, P., Suarez, I., Brayer, J., List, A. F., Sotomayor, E. M. (2005). The Immunomodulatory Drug Lenalidomide (CC5013; Revlimid), Enhances Antigen-Presenting Cell's Function Leading to Effective Priming of CD4+ T-Lymphocytes.. ASH ANNUAL MEETING ABSTRACTS 106: 2391-2391 [Abstract]  
• Fenaux, P., Ades, L. (2005). Erythropoietin for the anemia of low-risk myelodysplastic syndromes. Blood 106: 768-769 [Full Text]  
• Chng, W. J., Stadler, M., Ganser, A., List, A. F., Cazzola, M., Malcovati, L. (2005). Treatment of Myelodysplastic Syndromes. NEJM 352: 2134-2135 [Full Text]  
• Guinan, E. C. (2005). Aplastic Anemia: Management of Pediatric Patients. ASH Education Book 2005: 104-109 [Abstract] [Full Text]  
• Hellstrom-Lindberg, E. (2005). Update on Supportive Care and New Therapies: Immunomodulatory Drugs, Growth Factors and Epigenetic-Acting Agents. ASH Education Book 2005: 161-166 [Abstract] [Full Text]